Life Technologies Corp Signs Agreement with Harvard University

Life Technologies Corporation (NASDAQ:LIFE) announced that it has signed a research agreement with Harvard University, under which it has obtained exclusive rights to create characterization assays to evaluate human pluripotent stem cells.

As quoted in the press release:

The panel, which will be offered on the company’s market-leading semiconductor sequencing and PCR-based genetic analysis platforms, will help overcome major hurdles that impede stem cell technology from moving into the clinic. Current methods for evaluating pluripotency – the potential for induced pluripotent stem (iPS) cells to differentiate into any cell type – are laborious, costly and can produce ambiguous results.

Click here to read the full Life Technologies Corporation (NASDAQ:LIFE) press release.